My Awesome Newsletter

Archives
March 7, 2026

Abbott's $7B+ bond play & ASC equipment financing shifts

Supply Chain Pulse — 2026-03-07

Abbott is raising massive capital through bond sales to fund its Exact Sciences acquisition, signaling continued consolidation in diagnostics that could reshape vendor relationships. Meanwhile, ASCs are wrestling with the economics of expensive new cardiac devices, and Providence's asset sales highlight ongoing financial pressures across health systems.


Quick Hits

  • New York health system planning position cuts as industry layoffs continue (Modern Healthcare)
  • MUSC Health acquires primary care physician group in latest consolidation move (Modern Healthcare)
  • CBP says 45 days needed to implement tariff refund process for defunct levies (Supply Chain Dive - Healthcare)
  • Health systems reporting improved margins from higher volumes and efficiency gains (Modern Healthcare)
  • Amazon launches new agentic AI tool for healthcare providers (Modern Healthcare)

Abbott kicks off bond sale for Exact Sciences deal

Abbott is launching a significant bond offering to finance its acquisition of Exact Sciences, marking a major consolidation play in the diagnostics space. This merger will likely create a dominant player in glucose monitoring and cancer screening, potentially giving Abbott increased negotiating power with health systems and affecting pricing for diagnostic equipment and supplies.

Source: Modern Healthcare

How ASCs make the finances work for pulsed field ablation

ASCs are strategically evaluating the ROI on pulsed field ablation equipment, which requires substantial upfront investment in specialized devices, staff training, and facility modifications. Supply chain managers need to factor in not just the capital equipment costs but also ongoing consumables, maintenance contracts, and the specialized inventory requirements for these cardiac procedures.

Source: Modern Healthcare

Providence plans California hospital sale amid turnaround efforts

Providence is exploring the sale of California hospitals as part of broader asset divestiture efforts, following a trend of health systems shedding underperforming facilities. These sales often trigger supply chain disruptions as new owners may switch GPO relationships, vendor contracts, and standardization efforts—requiring supply chain teams to prepare for potential changes in their network relationships.

Source: Modern Healthcare

Private equity firm to buy Enhabit in $1.1B home health deal

Kinderhook Industries is acquiring Enhabit, one of the nation's largest home health providers with 376 locations across 34 states, for $1.1 billion. This consolidation could reshape the home health supply chain landscape, potentially affecting pricing and distribution strategies for medical equipment, consumables, and pharmaceuticals delivered to patients' homes.

Source: Modern Healthcare

DHL Expands Cold Chain Logistics for Life Sciences & Healthcare

DHL is significantly expanding its cold chain network with new dedicated airfreight routes and facilities connecting major pharmaceutical hubs globally. This infrastructure investment could improve temperature-controlled delivery reliability and reduce costs for hospitals managing sensitive biologics, vaccines, and specialty pharmaceuticals.

Source: Healthcare Purchasing News

Can reshoring and onshoring deliver manufacturing sustainability benefits?

Manufacturers are evaluating domestic production investments not just for tariff mitigation but also for supply chain resilience and sustainability goals. Healthcare supply chain leaders should monitor these shifts as they could affect lead times, pricing, and availability of medical devices and pharmaceuticals currently sourced internationally.

Source: Supply Chain Dive - Healthcare

States sue Trump in bid to halt 10% global tariff

Over 20 states are challenging the president's 10% global tariff through federal court, arguing executive overreach in implementing the trade policy. The legal challenge creates uncertainty for healthcare supply chains already grappling with potential price increases on imported medical devices, equipment, and pharmaceutical raw materials.

Source: Supply Chain Dive - Healthcare


You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe

Don't miss what's next. Subscribe to My Awesome Newsletter:
Powered by Buttondown, the easiest way to start and grow your newsletter.